Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioxcel Therapeutics ( (BTAI) ) has shared an announcement.
On February 12, 2026, BioXcel Therapeutics reported completing an updated market opportunity assessment for IGALMI for at-home treatment of acute agitation in patients with bipolar disorders or schizophrenia, informed by its SERENITY At-Home clinical study and a recently filed supplemental New Drug Application for outpatient use. The assessment, based on prescriber and payer research plus claims analyses, found a moderate to high unmet need in the current agitation landscape, identified roughly 2.3 million treated U.S. patients with frequent at-home agitation and up to 1.8 million IGALMI-eligible patients, and indicated strong prescriber and patient interest alongside expectations of broad payer coverage, suggesting a substantial potential expansion of IGALMI’s market and role in replacing dependence‑linked benzodiazepines.
The most recent analyst rating on (BTAI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Neutral.
The score is held down primarily by very weak financial performance (ongoing large losses, heavy cash burn, negative equity and high debt). Technical indicators are mixed and do not confirm a strong uptrend, while valuation lacks support due to negative earnings and no dividend. Offsetting factors include constructive corporate catalysts around IGALMI’s potential at-home label expansion and supportive clinical data.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for neuropsychiatric conditions, including acute agitation associated with bipolar disorders and schizophrenia. Its flagship product IGALMI is designed to address agitation episodes, with a growing focus on expanding use beyond clinical settings into at-home, outpatient care in the United States.
Average Trading Volume: 560,866
Technical Sentiment Signal: Sell
Current Market Cap: $36.3M
See more insights into BTAI stock on TipRanks’ Stock Analysis page.